Study of MLN4924 Plus Azacitidine in Treatment-naive Participants With Acute Myelogenous Leukemia (AML) Who Are 60 Years or Older

NCT01814826 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

64

Enrollment

INDUSTRY

Sponsor class

Conditions

Acute Myelogenous Leukemia

Interventions

DRUG: MLN4924
DRUG: Azacitidine

Sponsor

Millennium Pharmaceuticals, Inc.